SNCA and early-onset autosomal dominant Alzheimer disease: Indeed, chronic treatment of animals and in vitro NDs models of rotenone replicate certain features of Parkinson disease (PD) and Alzheimer disease (AD) including motor deficits, α-synuclein (SNCA) upregulation and aggregation, tau (MAPT) and amyloid β peptides (Aβ) accumulation, and dopaminergic and cholinergic cell death [4]–[10]; and chronic exposure to rotenone has been positively linked with PD [3].